As highlighted in the latest ICARE newsletter, a recent trial among BRCA1/2 carriers with breast cancer comparing PARP inhibitors to standard chemotherapy (Treatment of Physician’s Choice – TPC) found that after 25.7 months of follow up:
Overall survival in each group was:
- PARP: 18.9 months
- TPC: 15.5 months
The % alive at 3 years was:
- PARP: 40.8%
- TPC: 12.8%
Patients who received Olaparib for first line treatment showed the most benefit (22.6 months) compared to those not receiving as first line treatment (14.7 months). This benefit was seen regardless of hormone receptor status, BRCA status (BRCA1 versus BRCA2), site of metastasis, amount of prior treatment, or stage of disease progression.
Learn more here:
⤷ https://pubmed.ncbi.nlm.nih.gov/36893711/
Reference: Robson, et al. Eur J Cancer. 2023;184:39-47. PMID: 36893711.
⤷ https://pubmed.ncbi.nlm.nih.gov/36971103/
Reference: Senkus, et al. Int J Cancer. 2023;153(4):803‐814. PMID: 36971103.
We also encourage you to read the full ICARE newsletter at https://inheritedcancer.net/newsletters/